| Name | Title | Contact Details |
|---|
Able Medical Aids is a Largo, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ōmcare is a digital health company that aims to change the way the world cares by extending the reach of caregivers, increasing medication adherence, and improving treatment outcomes through the power of remote care and two-way video technology. By partnering with pharmacies, payers, providers, and family caregivers, Ōmcare strives to help people live healthier, more vibrant, independent lives and reduce healthcare cost. Ōmcare`s first product is called the Ōmcare Home Health Hub - a web-enabled platform that dispenses medication and provides two-way, audiovisual confirmation of medication adherence while facilitating social interaction and remote telehealth care. Ōmcare exists due to the rapidly aging population; high rate of medication nonadherence; a shortage of family and professional caregivers; continued increase in health care costs; consumer preference for in-home care and aging in place; changing reimbursement for home care services; and advancements remote monitoring and wearable technology.
Lewistown Florist proudly serves the Lewistown area. We are a family Owned Business, being in the Floral Industry for over 32 Years, Business is Over 75 Years old. Let Lewistown Florist be your first choice for flowers.
Johnson and Johnson Vision Care is a company committed to transforming the world's vision. Since our inception, we have strived to increase awareness of the importance of vision and vision care and to provide the world's most exceptional vision correction
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.